Navigation Links
The neural basis of the depressive self

Depression is actually defined by specific clinical symptoms such as sadness, difficulty to experience pleasure, sleep problems etc., present for at least two weeks, with impairment of psychosocial functioning. These symptoms guide the physician to make a diagnosis and to select antidepressant treatment such as drugs or psychotherapy.

At least 40% of depressed patients actually benefit from antidepressant treatment, whereas 20-30% of patients may suffer from chronic depression that negatively impacts their quality of life. In order to improve the efficiency of treatment and reduce the burden of depressive disorders, depression clearly needs to be defined at the neurobiological level.

Role of neurobiological markers in depression

Current research efforts are devoted to the study of the neural bases of depression and treatment induced changes using modern brain imaging techniques such as functional Magnetic Resonance Imaging (fMRI). Since many years it has become clear that depression is associated with dysfunction of specific brain regions involved in cognitive control and emotional response.

A recent fMRI-study showed that depressed patients had an abnormal activation of the medial prefrontal cortex (Figure 1; Lemogne et al. 2009). During this study, subjects had to judge whether personality traits described them or not (i.e. 'Am I selfish?'), or whether it described a generally desirable trait or not (i.e. 'Is it good or bad to be greedy?'). The dysfunction of the medial prefrontal region may explain specific complaints of depressed patients such as self-blame, rumination and feeling of guilt.

It was observed that this activation pattern was maintained over the course of depression after 8 weeks of antidepressant treatment. These results are difficult to interpret but suggest that, after remission of depression, some patients show persistent abnormalities of specific brain regions. Such abnormalities may indicate the need for complementary treatment such as cognitive behavioural therapy in order to reduce the risk of depressive recurrence.

Overall, these findings suggest that brain imaging studies could provide biomarkers of diagnosis and improve patients chances to responding to specific treatment modalities. Such neurobiological markers of depression may help psychiatrists to tailor antidepressant treatment to the brain and the biological needs of the patients.


In the general population, depression is still frequently associated with bad life style, impairment of volition and 'psychological weakness'. However, the results of brain imaging studies clearly have confirmed that depression is a true brain disease associated with dysfunction of specific brain regions involved in cognitive control and emotional response.

Depression needs to be defined at the neurobiological level in order to improve the efficiency of treatment and reduce the burden of depressive disorders.

Neurobiological markers of depression may help psychiatrists to target specific neural processes and regions involved in affective regulation and to tailor antidepressant treatment according to the biological needs of the patients. This could improve patients chances to responding to specific treatment modalities.


Contact: Sonja Mak
European College of Neuropsychopharmacology

Related medicine news :

1. Race and empathy matter on neural level
2. Neuralstem updates clinical trial progress
3. FDA approves first human neural stem cell clinical trial to treat brain tumors
4. Human neural stem cells restore motor function in mice with chronic spinal cord injury
5. Neuralstem files FDA application for first chronic spinal cord injury stem cell trial
6. Hurts so good -- neural clues to the calming effects of self-harm
7. Higher anxiety, depression among women may have basis in cell signals
8. Mount Sinai researchers find structural basis for incidence of skin cancers in a genetic disorder
9. Smoking increases depressive symptoms in teens
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... ... the perfect dish and pleasing the palates of attendees is of the utmost ... dish to a seasonal get-together, give these recipes a try this holiday season. ...
(Date:11/25/2015)... , ... November 26, 2015 , ... ... Commission (AUC), European Union (EU), ANDI Pan African Centres of Excellence, and public ... in Nairobi (UNON) for the opening of the 5th African Network for Drugs ...
(Date:11/25/2015)... Cleveland, OH (PRWEB) , ... November 25, 2015 , ... ... dental implants in Cleveland, OH , are invited to attend Dr. Mark Iacobelli’s Advanced ... 5th this year in Cleveland, OH. , As the co-founders of Advanced Implant ...
(Date:11/25/2015)... ... ... Smiles by Stevens is pleased to announce the addition of ... patients are aware of the benefits of Botox® in the treatment of moderate facial ... discomfort, soreness, and pain as a result of Jaw Tension, TMJ (temporo-mandibular joint) disorder, ...
(Date:11/25/2015)... ... November 25, 2015 , ... “While riding the bus, I saw a passenger ... thought there had to be a convenient and comfortable way to protect them from ... disabled individuals to safely travel during cold or inclement weather. In doing so, it ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... Nov. 25, 2015  Mindray Medical ... MR ), a leading developer, ... worldwide, today announced that it will ... of shareholders at the Company,s Hong Kong office ... Prince Edward West Road, Mongkok KL, Hong ...
(Date:11/25/2015)... - Will Also Offer Point ... (CME) --> - Will Also Offer ... (CME) --> - Will ... Education (CME) Elsevier , a world-leading ... feature latest diagnostic imaging textbooks and decision support tools, as well ...
(Date:11/25/2015)... 25, 2015 --> ... eine Lizenz für das Patent über eine neue Hepatitis-B-Behandlung, ... ENS-Lyon innehaben, an Enyo Pharma vergeben haben. ... Leben gerufenen und von Edelris gemeinsam mit seinen Partnern ... Behandlungsziel für HBV identifiziert, und es wurden neue Inhaltsstoffe ...
Breaking Medicine Technology: